SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/17 Vivos Inc 10-Q 9/30/17 53:2.8M M2 Compliance/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 264K 2: EX-31.1 Certification -- §302 - SOA'02 HTML 24K 3: EX-31.2 Certification -- §302 - SOA'02 HTML 24K 4: EX-32.1 Certification -- §906 - SOA'02 HTML 19K 11: R1 Document and Entity Information HTML 37K 12: R2 Condensed Balance Sheets HTML 89K 13: R3 Condensed Balance Sheets (Parenthetical) HTML 35K 14: R4 Condensed Statements of Operations (Unaudited) HTML 75K 15: R5 Condensed Statements of Cash Flow (Unaudited) HTML 105K 16: R6 Basis of Presentation and Significant Accounting HTML 40K Policies 17: R7 Going Concern HTML 27K 18: R8 Fixed Assets HTML 26K 19: R9 Intangible Assets HTML 24K 20: R10 Related Party Transactions HTML 22K 21: R11 Convertible Notes Payable HTML 40K 22: R12 Common Stock Options, Warrants, and Restricted HTML 69K Stock Units 23: R13 Stockholders' Equity HTML 23K 24: R14 Supplemental Cash Flow Information HTML 24K 25: R15 Commitments and Contingencies HTML 20K 26: R16 Subsequent Events HTML 20K 27: R17 Basis of Presentation and Significant Accounting HTML 45K Policies (Policies) 28: R18 Basis of Presentation and Significant Accounting HTML 33K Policies (Tables) 29: R19 Fixed Assets (Tables) HTML 25K 30: R20 Intangible Assets (Tables) HTML 24K 31: R21 Convertible Notes Payable (Tables) HTML 36K 32: R22 Common Stock Options, Warrants, and Restricted HTML 72K Stock Units (Tables) 33: R23 Basis of Presentation and Significant Accounting HTML 27K Policies - Schedule of Fair Value of Financial Instruments (Details) 34: R24 Going Concern (Details Narrative) HTML 34K 35: R25 Fixed Assets (Details Narrative) HTML 19K 36: R26 Fixed Assets - Schedule of Fixed Assets (Details) HTML 27K 37: R27 Intangible Assets (Details Narrative) HTML 20K 38: R28 Intangible Assets - Schedule of Intangible Assets HTML 25K (Details) 39: R29 Related Party Transactions (Details Narrative) HTML 36K 40: R30 Convertible Notes Payable (Details Narrative) HTML 65K 41: R31 Convertible Notes Payable - Schedule of HTML 42K Convertible Notes Payable (Details) 42: R32 Convertible Notes Payable - Schedule of HTML 59K Convertible Notes Payable (Details) (Parenthetical) 43: R33 Common Stock Options, Warrants and Restricted HTML 24K Stock Units (Details Narrative) 44: R34 Common Stock Options, Warrants and Restricted HTML 69K Stock Units - Schedule Summarizes Changes in Stock Option (Details) 45: R35 Common Stock Options, Warrants and Restricted HTML 69K Stock Units - Schedule Summarizes Changes in Stock Warrants (Details) 46: R36 Common Stock Options, Warrants and Restricted HTML 35K Stock Units - Schedule Summarizes Changes in Restricted Stock Units (Details) 47: R37 Stockholders' Equity (Details Narrative) HTML 80K 48: R38 Supplemental Cash Flow Information (Details HTML 73K Narrative) 49: R39 Commitments and Contingencies (Details Narrative) HTML 19K 50: R40 Subsequent Events (Details Narrative) HTML 37K 52: XML IDEA XML File -- Filing Summary XML 92K 51: EXCEL IDEA Workbook of Financial Reports XLSX 45K 5: EX-101.INS XBRL Instance -- admd-20170930 XML 729K 7: EX-101.CAL XBRL Calculations -- admd-20170930_cal XML 126K 8: EX-101.DEF XBRL Definitions -- admd-20170930_def XML 353K 9: EX-101.LAB XBRL Labels -- admd-20170930_lab XML 680K 10: EX-101.PRE XBRL Presentations -- admd-20170930_pre XML 520K 6: EX-101.SCH XBRL Schema -- admd-20170930 XSD 116K 53: ZIP XBRL Zipped Folder -- 0001493152-17-012763-xbrl Zip 71K
EXHIBIT 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael K. Korenko, certify that:
1. | I have reviewed this quarterly report on Form 10-Q of Advanced Medical Isotope Corporation; | |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; | |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; | |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and | |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 13, 2017
/s/ Michael K. Korenko | |
Michael K. Korenko | |
Chief Executive Officer | |
(Principal Executive Officer) |
C:
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 11/13/17 | None on these Dates | ||
For Period end: | 9/30/17 | |||
List all Filings |